4-(Phenylamino)-[1,4]dioxano[2,3-g]quinazoline derivatives and process for preparing the same
申请人:——
公开号:US20030045537A1
公开(公告)日:2003-03-06
The present invention relates to 4-(phenylamino)-[1,4]dioxano[2,3-g]quinazoline derivatives which inhibit tyrosine kinase of epidermal growth factor receptor (EGFR), and pharmaceutically acceptable salts, hydrates and solvates thereof, and a process for preparing the same. Since 4-(phenylamino)-[1,4]dioxano[2,3-g]quinazoline derivatives of the invention have a high solubility in water and inhibit the activity of EGFR tyrosine kinase and the growth of cancer cells, they can be practically applied in the treatment of overproliferation-associated diseases such as cancer.
本发明涉及抑制表皮生长因子受体(EGFR)的酪氨酸激酶的4-(苯胺基)-[1,4]二氧杂环[2,3-g]喹唑啉衍生物,以及其药学上可接受的盐、水合物和溶剂合物,以及其制备方法。由于本发明的4-(苯胺基)-[1,4]二氧杂环[2,3-g]喹唑啉衍生物在水中具有较高的溶解度,并且能够抑制EGFR酪氨酸激酶的活性和癌细胞的生长,因此它们可以在治疗癌症等过度增殖相关疾病中得到实际应用。